Exploration of Neuroprotective Therapy

Pathology	Difference with RCVS
Cluster headache	Episodic
SAH aneurysmal	Findings of ruptured aneurysm
Primary angiitis of the CNS	No thunderclap headache Ischemic infarctions Abnormal CSF

Declarations

Author contributions

ARF: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. LRS: Investigation, Writing—original draft, Writing—review & editing. NMG: Validation, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Song TJ, Lee KH, Li H, Kim JY, Chang K, Kim SH, et al. Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review. Eur Rev Med Pharmacol Sci. 2021;25:3519–29. [DOI] [PubMed]

Coral-Casas J, Ricaurte-Fajardo A, McCormick SJ, Baracaldo I, Jimenez CA, Mejia JA. Reversible cerebral vasoconstriction syndrome associated with anastrozole: an unusual cause of high impact. Rev Neurol. 2019;68:250–4. Spanish. [DOI] [PubMed]

Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: Epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol. 2015;36:1392–9. [DOI] [PubMed] [PMC]

Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11:906–17. [DOI] [PubMed]

Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146:34–44. [DOI] [PubMed]

Sheikh HU, Mathew PG. Reversible cerebral vasoconstriction syndrome: updates and new perspectives. Curr Pain Headache Rep. 2014;18:414. [DOI] [PubMed]

Vilela P. Acute stroke differential diagnosis: stroke mimics. Eur J Radiol. 2017;96:133–44. [DOI] [PubMed]

Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130:3091–101. [DOI] [PubMed]

Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke. 2010;41:2505–11. [DOI] [PubMed]

10.

Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2010;67:648–56. [DOI] [PubMed]

11.

Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68:1005–12. [DOI] [PubMed]

12.

Gupta S, Zivadinov R, Ramasamy D, Ambrus JL Jr. Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature. Clin Rheumatol. 2014;33:1829–33. [DOI] [PubMed]

13.

Katz BS, Fugate JE, Ameriso SF, Pujol-Lereis VA, Mandrekar J, Flemming KD, et al. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71:68–73. [DOI] [PubMed]

14.

Cantu C, Arauz A, Murillo-Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34:1667–72. [DOI] [PubMed]

15.

Nighoghossian N, Derex L, Trouillas P. Multiple intracerebral hemorrhages and vasospasm following antimigrainous drug abuse. Headache. 1998;38:478–80. [DOI] [PubMed]

16.

Kato Y, Hayashi T, Mizuno S, Horiuchi Y, Ohira M, Tanahashi N, et al. Triptan-induced reversible cerebral vasoconstriction syndrome: two case reports with a literature review. Intern Med. 2016;55:3525–8. [DOI] [PubMed] [PMC]

17.

Wolff V, Lauer V, Rouyer O, Sellal F, Meyer N, Raul JS, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011;42:1778–80. [DOI] [PubMed]

18.

Koopman K, Uyttenboogaart M, Luijckx GJ, De Keyser J, Vroomen PC. Pitfalls in the diagnosis of reversible cerebral vasoconstriction syndrome and primary angiitis of the central nervous system. Eur J Neurol. 2007;14:1085–7. [DOI] [PubMed]

19.

John S, Singhal AB, Calabrese L, Uchino K, Hammad T, Tepper S, et al. Long-term outcomes after reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016;36:387–94. [DOI] [PubMed]

20.

Chen SP, Chung YT, Liu TY, Wang YF, Fuh JL, Wang SJ. Oxidative stress and increased formation of vasoconstricting F2-isoprostanes in patients with reversible cerebral vasoconstriction syndrome. Free Radic Biol Med. 2013;61:243–8. [DOI] [PubMed]

21.

Yang L, Bai HX, Zhao X, Xiao Y, Tan L. Postpartum cerebral angiopathy presenting with non-aneurysmal subarachnoid hemorrhage and interval development of neurological deficits: a case report and review of literature. Neurol India. 2013;61:517–22. [DOI] [PubMed]

22.

Jensen J, Leonard J, Salottolo K, McCarthy K, Wagner J, Bar-Or D. The epidemiology of reversible cerebral vasoconstriction syndrome in patients at a Colorado comprehensive stroke center. J Vasc Interv Neurol. 2018;10:32–8. [PubMed] [PMC]

23.

Akhter T, Larsson A, Larsson M, Wikström AK, Naessen T. Artery wall layer dimensions during normal pregnancy: a longitudinal study using noninvasive high-frequency ultrasound. Am J Physiol Heart Circ Physiol. 2013;304:H229–34. [DOI] [PubMed]

24.

Majic T, Aiyagari V. Cerebrovascular manifestations of pheochromocytoma and the implications of a missed diagnosis. Neurocrit Care. 2008;9:378–81. [DOI] [PubMed]

25.

Tischler AS, Kimura N, Mcnicol AM. Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci. 2006;1073:557–70. [DOI] [PubMed]

26.

Arenas-Beltran MA, Ricaurte-Fajardo A, Ocampo-Navia MI, Baracaldo I, Mejia JA, Coral-Casas J. Reversible cerebral vasoconstriction syndrome secondary to secreting jugular paraganglioma. Rev Neurol. 2019;69:220–2. Spanish. [DOI] [PubMed]

27.

Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010;8:1417–21. [DOI] [PubMed] [PMC]

28.

Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert Rev Neurother. 2011;11:1265–76. [DOI] [PubMed]

29.

De la Torre-Colmenero JD, Arjona-Padillo A, Fernandez-Perez J. Reversible cerebral vasoconstriction syndrome following smoking cessation and treatment with bupropion. Rev Neurol. 2018;66:322–3. Spanish. [PubMed]

30.

Topcuoglu MA, Jha RM, George J, Frosch MP, Singhal AB. Hemorrhagic primary CNS angiitis and vasoconstrictive drug exposure. Neurol Clin Pract. 2017;7:26–34. [DOI] [PubMed] [PMC]

31.

Arrigan MT, Heran MKS, Shewchuk JR. Reversible cerebral vasoconstriction syndrome: an important and common cause of thunderclap and recurrent headaches. Clin Radiol. 2018;73:417–27. [DOI] [PubMed]

32.

Wolff V, Ducros A. Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache. 2016;56:674–87. [DOI] [PubMed]

33.

Ducros A, Wolff V. The typical thunderclap headache of reversible cerebral vasoconstriction syndrome and its various triggers. Headache. 2016;56:657–73. [DOI] [PubMed]

34.

Ducros A, Bousser MG. Thunderclap headache. BMJ. 2013;346:e8557. [DOI] [PubMed]

35.

Choi HA, Lee MJ, Choi H, Chung CS. Characteristics and demographics of reversible cerebral vasoconstriction syndrome: a large prospective series of Korean patients. Cephalalgia. 2018;38:765–75. [DOI] [PubMed]

36.

Qubty W, Irwin SL, Fox CK. Review on the diagnosis and treatment of reversible cerebral vasoconstriction syndrome in children and adolescents. Semin Neurol. 2020;40:294–302. [DOI] [PubMed]

37.

Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1–211. [DOI] [PubMed]

38.

Calic Z, Cappelen-Smith C, Zagami AS. Reversible cerebral vasoconstriction syndrome. Intern Med J. 2015;45:599–608. [DOI] [PubMed] [PMC]

39.

Rocha EA, Topcuoglu MA, Silva GS, Singhal AB. RCVS₂ score and diagnostic approach for reversible cerebral vasoconstriction syndrome. Neurology. 2019;92:e639–47. [DOI] [PubMed]

40.

Skeik N, Porten BR, Kadkhodayan Y, McDonald W, Lahham F. Postpartum reversible cerebral vasoconstriction syndrome: review and analysis of the current data. Vasc Med. 2015;20:256–65. [DOI] [PubMed]

41.

Kraayvanger L, Berlit P, Albrecht P, Hartung HP, Kraemer M. Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis? Clin Exp Immunol. 2018;193:341–5. [DOI] [PubMed] [PMC]

42.

Velez A, McKinney JS. Reversible cerebral vasoconstriction syndrome: a review of recent research. Curr Neurol Neurosci Rep. 2013;13:319. [DOI] [PubMed]

43.

Terasawa Y, Arai A, Sakai K, Mitsumura H, Iguchi Y. Transcranial color-coded sonography findings of patients with reversible cerebral vasoconstriction syndromes. J Clin Neurosci. 2019;61:290–2. [DOI] [PubMed]

44.

Ducros A. Reversible cerebral vasoconstriction syndrome. Rev Neurol. 2010;166:365–76. French. [DOI] [PubMed]

45.

Edlow BL, Kasner SE, Hurst RW, Weigele JB, Levine JM. Reversible cerebral vasoconstriction syndrome associated with subarachnoid hemorrhage. Neurocrit Care. 2007;7:203–10. [DOI] [PubMed]

46.

Ghosh PS, Rothner AD, Zahka KG, Friedman NR. Reversible cerebral vasoconstriction syndrome: a rare entity in children presenting with thunderclap headache. J Child Neurol. 2011;26:1580–4. [DOI] [PubMed]

47.

Levitt A, Zampolin R, Burns J, Bello JA, Slasky SE. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: distinct clinical entities with overlapping pathophysiology. Radiol Clin North Am. 2019;57:1133–46. [DOI] [PubMed]

48.

Valencia-Mendoza M, Ramírez-Rodríguez N, Vargas-Avila N, Peña-Ortiz A, Corzo-Villamizar M, Serna-Ramírez L, et al. Fatal reversible cerebral vasoconstriction syndrome: a systematic review of case series and case reports. J Clin Neurosci. 2019;70:183–8. [DOI] [PubMed]

49.

Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88:228–36. [DOI] [PubMed] [PMC]

50.

Mijalski C, Dakay K, Miller-Patterson C, Saad A, Silver B, Khan M. Magnesium for treatment of reversible cerebral vasoconstriction syndrome: case series. Neurohospitalist. 2016;6:111–3. [DOI] [PubMed] [PMC]

51.

Raven ML, Ringeisen AL, McAllister AR, Knoch DW. Reversible cerebral vasoconstriction syndrome presenting with visual field defects. J Neuroophthalmol. 2016;36:187–90. [DOI] [PubMed]

52.

Barpujari A, Patel C, Zelmonovich R, Clark A, Patel D, Pierre K, et al. Pharmaceutical management for subarachnoid hemorrhage. Recent Trends Pharm Sci Res. 2021;3:16–30. [PubMed] [PMC]

53.

Maciel CB, Gilmore EJ. Seizures and epileptiform patterns in SAH and their relation to outcomes. J Clin Neurophysiol. 2016;33:183–95. [DOI] [PubMed]

54.

Sorrentino ZA, Laurent D, Hernandez J, Davidson C, Small C, Dodd W, et al. Headache persisting after aneurysmal subarachnoid hemorrhage: a narrative review of pathophysiology and therapeutic strategies. Headache. 2022;62:1120–32. [DOI] [PubMed]

55.

Mehkri Y, Hanna C, Sriram S, Lucke-Wold B, Johnson RD, Busl K. Calcitonin gene-related peptide and neurologic injury: an emerging target for headache management. Clin Neurol Neurosurg. 2022;220:107355. [DOI] [PubMed]

56.

Kim BS, Park YK, Sunwoo MK, Yu HJ, Jeong EH, Kim DY. Is the presence of headache indispensable in diagnosing reversible cerebral vasoconstriction syndrome? J Clin Neurol. 2019;15:588–90. [DOI] [PubMed] [PMC]